Literature DB >> 27725677

Targeted therapies: What have we learned from SHIVA?

Christophe Le Tourneau1, Razelle Kurzrock2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27725677     DOI： 10.1038/nrclinonc.2016.164

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Authors:  Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Denis L Jardim; Denis L Fontes Jardim; Maria Schwaederle; Caimiao Wei; J Jack Lee; David S Hong; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2015-09-15       Impact factor: 13.506

3.  The spectrum of clinical trials aiming at personalizing medicine.

Authors:  Christophe Le Tourneau; Maud Kamal; Marie Alt; Loic Verlingue; Vincent Servois; Marie-Paule Sablin; Nicolas Servant; Xavier Paoletti
Journal:  Chin Clin Oncol       Date:  2014-06

4.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Authors:  Filip Janku; David S Hong; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Gerald S Falchook; Apostolia M Tsimberidou; Vanda M Stepanek; Stacy L Moulder; J Jack Lee; Rajyalakshmi Luthra; Ralph G Zinner; Russell R Broaddus; Jennifer J Wheler; Razelle Kurzrock
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

5.  Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Gregory A Daniels; David E Piccioni; Santosh Kesari; Teresa L Helsten; Lyudmila A Bazhenova; Julio Romero; Paul T Fanta; Scott M Lippman; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

6.  Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

Authors:  Jennifer J Wheler; Filip Janku; Aung Naing; Yali Li; Bettzy Stephen; Ralph Zinner; Vivek Subbiah; Siqing Fu; Daniel Karp; Gerald S Falchook; Apostolia M Tsimberidou; Sarina Piha-Paul; Roosevelt Anderson; Danxia Ke; Vincent Miller; Roman Yelensky; J Jack Lee; David S Hong; Razelle Kurzrock
Journal:  Cancer Res       Date:  2016-05-18       Impact factor: 12.701

Review 7.  Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Authors:  Christophe Le Tourneau; Maud Kamal; Apostolia-Maria Tsimberidou; Philippe Bedard; Gaëlle Pierron; Céline Callens; Etienne Rouleau; Anne Vincent-Salomon; Nicolas Servant; Marie Alt; Roman Rouzier; Xavier Paoletti; Olivier Delattre; Ivan Bièche
Journal:  J Natl Cancer Inst       Date:  2015-11-23       Impact factor: 13.506

8.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

9.  Emerging landscape of oncogenic signatures across human cancers.

Authors:  Giovanni Ciriello; Martin L Miller; Bülent Arman Aksoy; Yasin Senbabaoglu; Nikolaus Schultz; Chris Sander
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330
  9 in total
  13 in total

1.  Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Authors:  Apostolia-Maria Tsimberidou; David S Hong; Yang Ye; Carrie Cartwright; Jennifer J Wheler; Gerald S Falchook; Aung Naing; Siqing Fu; Sarina Piha-Paul; Filip Janku; Funda Meric-Bernstam; Patrick Hwu; Bryan Kee; Merrill S Kies; Russell Broaddus; John Mendelsohn; Kenneth R Hess; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2017-09-08

Review 2.  Precision medicine needs randomized clinical trials.

Authors:  Everardo D Saad; Xavier Paoletti; Tomasz Burzykowski; Marc Buyse
Journal:  Nat Rev Clin Oncol       Date:  2017-02-07       Impact factor: 66.675

Review 3.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

4.  Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.

Authors:  Cheyennedra C Bieg-Bourne; Sherri Z Millis; David E Piccioni; Paul T Fanta; Michael E Goldberg; Juliann Chmielecki; Barbara A Parker; Razelle Kurzrock
Journal:  Cancer Res       Date:  2017-09-22       Impact factor: 12.701

Review 5.  Strategies for Testing Intervention Matching Schemes in Cancer.

Authors:  Nicholas J Schork; Laura H Goetz; James Lowey; Jeffrey Trent
Journal:  Clin Pharmacol Ther       Date:  2020-07-24       Impact factor: 6.875

6.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Authors:  Ryosuke Okamura; Amélie Boichard; Shumei Kato; Jason K Sicklick; Lyudmila Bazhenova; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2018-11-15

7.  A robust targeted sequencing approach for low input and variable quality DNA from clinical samples.

Authors:  Austin P So; Anna Vilborg; Yosr Bouhlal; Ryan T Koehler; Susan M Grimes; Yannick Pouliot; Daniel Mendoza; Janet Ziegle; Jason Stein; Federico Goodsaid; Michael Y Lucero; Francisco M De La Vega; Hanlee P Ji
Journal:  NPJ Genom Med       Date:  2018-01-15       Impact factor: 8.617

8.  Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.

Authors:  Hitendra Patel; Ryosuke Okamura; Paul Fanta; Charmi Patel; Richard B Lanman; Victoria M Raymond; Shumei Kato; Razelle Kurzrock
Journal:  J Hematol Oncol       Date:  2019-12-04       Impact factor: 17.388

9.  Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Authors:  Sadakatsu Ikeda; Sheryl K Elkin; Brett N Tomson; Jennifer L Carter; Razelle Kurzrock
Journal:  Cancer Biol Ther       Date:  2018-10-19       Impact factor: 4.742

10.  Community-driven development of a modified progression-free survival ratio for precision oncology.

Authors:  Andreas Mock; Christoph E Heilig; Simon Kreutzfeldt; Daniel Huebschmann; Christoph Heining; Evelin Schröck; Benedikt Brors; Albrecht Stenzinger; Dirk Jäger; Richard Schlenk; Hanno Glimm; Stefan Fröhling; Peter Horak
Journal:  ESMO Open       Date:  2019-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.